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Summary Twelve premenopausal patients with advanced breast cancer were randomised to receive 3.75 or
7.5 mg of a slow release formulation of the luteinising hormone releasing hormone agonist leuprorelin once
every 4 weeks. All patients were oestrogen receptor positive or unknown. Serum levels of gonadotrophins and
oestrogens were suppressed markedly by both doses. All oestrogen values during treatment were within the
postmenopausal range except for a single oestradiol level (274 pmol I1-) in one patient on the lower dose.
There was no other indication that this lower dose was less effective as an oestrogen suppressant. There were
two objective responders to the 3.75 mg dose and three to the 7.5 mg dose. Toxicity was confined almost
entirely to hot flushes which occurred in 11/12 patients. We conclude that the slow release formulation of
leuprorelin is effective in breast cancer treatment and that there is no major detriment to the use of the 3.75
rather than 7.5 mg dose.
Numerous studies have demonstrated that luteinising hor-
mone releasing hormone agonists (LHRHa's) are effective in
the treatment of prostatic cancer (Jacobi et al., 1987; Smith
et al., 1985; Donnelly & Milstead, 1987) and breast cancer
(Harvey et al., 1985; Klijn, 1984; Williams et al., 1986). This
is due to the 'down-regulation' of LHRH receptors by the
drugs, which results in a fall in gonadotrophin levels and a
consequent reduction in the level of gonadal steroid produc-
tion (Sandow, 1983). The response rate is higher in
premenopausal patients in breast cancer as might be expected
for a drug with this action. The small number of responses in
postmenopausal patients may be due to reduced ovarian
androgen secretion with a consequent fall in circulating oest-
rogen levels (Dowsett et al., 1988; Crighton et al., 1989).
Leuprorelin is a synthetic nonapeptide LHRHa (D-Leu6
DES Gly NH2iO GnRH ethylamide) which lacks the
aminoacid glycine at position 10 and has leucine substituted
for glycine at position 6 of natural LHRH. Earlier clinical
studies required daily administration in aqueous solution
(Harvey et al., 1985), but a more convenient sustained release
formulation has now been developed, in which the agonist is
microencapsulated in polylactic and polyglycolic acid. It has
been found that the compound is equally effective endocrino-
logically in prostatic cancer as once monthly doses of either
7.5 or 3.75 mg (Isurugi et al., 1988). This is the first report of
the use of the slow-release formulation in premenopausal
women. A detailed endocrine study was conducted to com-
pare the doses of 3.75 and 7.5 mg in 12 patients, to determine
whether there was any contraindication to further study of
the lower dose in a larger group of patients.
Patients and methods
Twelve premenopausal patients with histologically or
cytologically diagnosed, assessable advanced breast cancer
were recruited to the study. Primary tumours were either
oestrogen receptor (ER) positive or unknown. All patients
had regular menstrual cycles at the time of recruitment, and
none had received previous endocrine or cytotoxic chemo-
therapy for metastatic disease. Three patients had previously
received adjuvant cytotoxic chemotherapy, but any effects of
this on menstrual function had been lost before starting
leuprorelin. Six patients were allocated to receive either 3.75
or 7.5 mg of leuprorelin SR (slow release) suspended in 2 ml
of saline once every 4 weeks as an abdominal subcutaneous
injection. The allocation was according to a predetermined
randomised list held by the pharmacy. It was aimed to start
treatment between days 0 and 10 of the menstrual cycle
where the patients' clinical status allowed to avoid the
likelihood of a surge of oestradiol release. This was achieved
in eight patients. The demographic data for each group are
shown in Table I. Patients were followed up at monthly
intervals, and stayed on treatment until there was objective
evidence of progressive disease. Response was assessed ac-
cording to standard WHO criteria. The relatively small
number compared in this study was according to the aim of
seeking to document only a large difference between the
doses.
Blood samples were drawn from patients prior to treat-
ment and 1, 2, 3, 4, 6, 8, 10 and 12 weeks after starting
treatment. The samples were allowed to clot and the resultant
serum was stored at - 20°C until analysis. The following
analyses were performed by previously described immuno-
assays: luteinising hormone (LH) and follicle stimulating hor-
mone (FSH) (Ferguson et al., 1982); oestradiol (Dowsett et
al., 1987), oestrone (Harris et al., 1983). Serum levels of
androstenedione were measured using the Biogenesis kit. This
is a direct assay employing an iodinated tracer in which the
only cross-reactions of greater than 0.1 % were to 11-
deoxycortisol (1.2%) and isoandrosterone (0.3%). Within-
and between-assay coefficients of variation were 7.5% and
8.6%, respectively. Serum levels of testosterone were
measured using the St Thomas Hospital Testosterone kit
(Wheeler et al., 1983). In this assay, the serum is first ex-
tracted with ether and this extract is subject to immunoassay
using an iodinated tracer. The antiserum cross-reacts 20%
with 5adihydrotestosterone. All other cross-reactions were
less than 0.1%. Within- and between-assay coefficients of
variation were 3.6% and 5.8%, respectively.
Statistical analysis
Mann-Whitney tests were performed between doses for each
of the parameters at 4, 8 and 12 weeks after starting treat-
ment. Wilcoxon signed-ranked tests for paired data were
performed to test for changes between pretreatment levels
and each of the three on-treatment time points. Since no
significant differences were found in the data between the
doses the data were pooled to test for differences between
time points. Non-parametric tests were selected to ensure a
valid approach to the analysis in the absence of sufficient
data to determine the fit to a normal distribution. These time
points were selected since any recovery of endocrine function
as a result of undertreatment would be most apparent at
these times.
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Table I Demographic and response data for patients
Day of
menstrual Duration
Age Weight Disease Previous cycle treatment Response of treatment
Patient no. (years) (kg) ER sites treatment started to leuprorelin (weeks)
3.75 mg dose 1 40 73 + bo. nil 7 SD 88
2 49 61 unk. br., ln. nil 3 PR 80
3 40 92 + bo. adj. CMF 25 SD 16
4 38 64 + bo., lu. adj. CMF 14 SD 56
5 40 48 + bo., lu. nil 10 PR 56+
6 33 55 unk. br. nil ? PD 12
7.5mg dose 7 42 72 + In., med. nil 2 CR 72
8 29 65 unk. br., ln. nil 6 PD 12
9 38 72 + br. nil 23 SD 16
10 42 52 unk. bo. nil 3 PR 28
11 50 48 unk. br., In., bo. nil 1 PR 60+
12 40 65 + br., In., bo. adj. CMF 3 SD 36
Unk., unknown; adj., adjuvant; bo., bone; br., breast; In., lymph nodes; lu., lung; med., mediastinum; CR, complete response; PR, partial
response; SD, stable disease; PD, progressive disease.
Results
The clinical responses of the patients are shown for each dose
(Table I). Responses were seen with both doses. For the
lower dose there were two objective responders, three
patients with stable disease and one with progressive disease,
whilst for the higher dose the figures were three, two and
one, respectively. There was therefore a 42% objective re-
sponse rate overall (95% confidence interval 15-72%). In
addition three of the patients were stabilised for over 6
months. The median length of time on treatment for the
whole group was 46 weeks.
Ten of the patients had a menstrual bleed within 4 weeks
of starting treatment but did not menstruate further during
the treatment. The other two did not menstruate at all during
treatment. One of these patients started treatment on day 2
of the cycle whilst the other was on day 14. Eleven of the 12
patients complained of hot flushes. Other side-effects were
very few: two patients had weight gain and one patient
complained of crying bouts.
The mean levels of LH, FSH, oestradiol, oestrone, testo-
sterone and androstenedione before and during treatment are
shown in the figure. LH levels fell to mean levels of about
3 IU 1' in both groups by week 3. This value is in the range
found during the early follicular phase of the menstrual cycle
and is consistent with an effective suppression of ovarian
steroidogenesis. There was little variability in the LH levels
thereafter and there was no significant difference between
doses at weeks 4, 8 or 12. Values at each of these time points
were significantly below pretreatment values (P = 0.002,
0.001 and 0.004, respectively). The pattern for FSH was very
different from the pattern for LH but was quite similar
between the doses. FSH levels fell during the first 2 weeks of
treatment but from week 4 (P = 0.01 versus pretreatment)
onwards there was a progressive increase to values not
significantly different from baseline.
All patients had oestradiol levels greater than 100 pmol 1'
(the upper limit of the laboratory normal range for post-
menopausal women) prior to treatment. By week 4 all values
had fallen to below 50 pmol I' (P = 0.002). Thereafter a
single value above 100 pmol I' was found in one patient
(patient no. 6, week 8, 274 pmol 1'). This is reflected in the
small separation of the curves of the two doses at this time
point in Figure 1. There was, however, no significant
difference between the doses in their effects on oestradiol
levels at weeks 4, 8 or 12. Oestrone levels also fell in both
groups (P = 0.04, 0.008 and 0.004 at 4, 8 and 12 weeks,
respectively). In general the levels were similar between the
two dosage groups but the 3.75 mg group had significantly
lower values on week 12. All on treatment values were within
the laboratory normal range (70-250pmol 1') for post-
menopausal females.
For testosterone there were small and statistically non-
significant falls in mean values on treatment which were not
apparent for androstenedione. The difference between the
testosterone levels at week 4 approached statistical
significance (P = 0.07) but otherwise there was no indication
of a difference between the doses in these androgen levels.
The mean on-treatment value remained within the normal
range at all times (testosterone 0.5-2.5 nmol 1I-; andro-
stenedione 1.0-7.0 nmol 1`).
There was little consistent change in prolactin levels during
treatment and no marked difference between doses (data not
shown). For each dose one patient had levels of over 1,000
mIU 1-1 during treatment (patient nos 4 and 9).
Discussion
Over recent years the clinical use of LHRH agonists has been
explored in many diseases which are at least partly dependent
on sex steroids and these agents have become accepted as
alternatives for the first line treatment of advanced prostatic
and premenopausal breast cancer (Jackson et al., 1989). The
initial clinical investigations with each of these agonists were
made giving subcutaneous once daily doses (for leprorelin;
Harvey et al., 1985). However, the majority of the clinical
applications warrant prolonged use of the agonists and, more
recently, sustained release preparations have been developed
which can be used to suppress gonadal function for 4 weeks
after a single injection. This is the first report of the use of
the slow-release formulation of leuprorelin in premenopausal
women. The comparison of doses was undertaken to deter-
mine whether there were any marked differences in the
effectiveness of the 3.75 and 7.5 mg doses of leuprorelin.
The study was designed with the prime objective of deter-
mining whether there were differences in the oestrogen sup-
pressive effects of the doses, which would indicate that the
lower dose was ineffective. The data suggest that the two
doses do not differ markedly in this respect. The important
parameters, oestradiol and oestrone, were suppressed to a
very similar extent. Indeed the only statistically significant
difference was the finding that at 12 weeks oestrone levels
were suppressed to a greater extent by the lower dose. It
seems likely that this difference has occurred by chance.
There was one observation of a high on-treatment oestradiol
level in a patient on the lower dose. We have previously
found a 4-5% incidence of such values in endometriosis
patients on 3.6 mg goserelin monthly (Dowsett et al., 1990),
which is an effective dose in premenopausal breast cancer
patients. The pattern of suppression of oestradiol was similar
to that found previously when leuprorelin was given by daily
subcutaneous injections (Harvey et al., 1985). There was no
indication of an early surge in LH, FSH or oestradiol levels
as has been seen in some studies with LHRH agonists
(Nicholson et al., 1984, 1987). This may have been due to the836 M. DOWSETT et al.
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Figure 1 Mean hormone levels before and during treatment with 4-weekly injections of 3.75 mg (0) and 7.5 mg (*) leuprorelin.
Error bars are not shown for the sake of clarity and because they would not be inferential in this presentation.
first of our blood samples being drawn only after 7 days
treatment.
Clearly the small number of patients compared in this
study require caution to be exercised in the interpretation of
the results. All the same it would be correct to say that it is
unlikely that there is a major difference between the two
doses in their suppression of ovarian function. It would thus
be reasonable to conduct larger, definitive studies of the
efficacy of the lower dose. This is also supported by the
observation that there were two objective responders to the
low dose.
The disparity in the effects on LH and FSH are similar to
those previously reported with long-term monitoring of
LHRH agonists (Santen et al., 1986; Nicholson et al., 1987).
The mechanism of the recovery of FSH levels is not known
but it could relate to the release ofinhibin by the ovaries as a
response to reduced FSH secretion.
The lack of serious clinical side effects with either dose of
leuprorelin and the response of five of the 12 patients sug-
gests that this drug should be pursued for premenopausal
breast cancer treatment. It seems appropriate that these
studies should include the dose of 3.75 mg per 4 weeks.
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